Elicio Therapeutics, Inc.·Healthcare
In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), the event-driven primary disease-free survival (“DFS”) analysis is anticipated mid-year 2026 The Company raised net proceeds of approximately $8.0 million in Q1 2026 and an additional $5.0 million in Q2 2026 to date, for aggregate net proceeds of approximately $13.0 million, through its established at-the-market program Projected cash runway beyond the expected AMPLIFY-7P Phase 2 final DFS data BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the quarter ended March 31, 2026, and provided recent corporate and clinical updates. “We remain focused on advancing the Phase 2 AMPLIFY-7P trial and anticipate reaching the event-driven primary DFS analysis of ELI-002 7P in post-resection KRAS-driven PDAC mid-year 2026,” said Robert Connelly, Chief Executive Officer of Elicio.
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, Christopher Haqq, MD, PhD, Executive Vice President, Head of Research and Development and Chief Medical Officer, Pete DeMuth, PhD, Chief Scientific Officer, and Preetam Shah, MBA, PhD, Chief Strategy and Financial Officer, will participate in the upcoming Bank of America Healthcare Conference, taking place May 12-14, 2026, in Las Vegas, NV. Bank of America Healthcare Conference Format: Company presentation Date: Thursday, May 14, 2026 Time: 12:20 PM ET The live webcast and replay of the presentation will be available HERE and on Elicio's Events page for 90 days following the event.
Elicio Therapeutics (ELTX) is approaching a pivotal trial readout for its KRAS peptide vaccine, positioning 2026 as a critical year for KRAS therapies. Imminent data from ELTX's pipeline could be a significant catalyst, despite ongoing concerns about the company's cash position. Financial overview highlights a looming cash crisis, underscoring the importance of upcoming clinical milestones for ELTX.
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2026, Elicio granted an aggregate of 21,210 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications. Advancements in Novel Immunotherapeutics in The Oncology Battle To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpg Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.
The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Elicio Therapeutics (ELTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
